Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Mussini C, et al. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. PLoS One. 2015. PMID: 26640953 Free PMC article.
Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. d'Arminio Monforte A, et al. AIDS. 1998 Sep 10;12(13):1631-7. doi: 10.1097/00002030-199813000-00010. AIDS. 1998. PMID: 9764782 Clinical Trial.
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M. d'Arminio Monforte A, et al. AIDS. 2000 Mar 31;14(5):499-507. doi: 10.1097/00002030-200003310-00005. AIDS. 2000. PMID: 10780712 Clinical Trial.
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B. Mussini C, et al. J Infect Dis. 2000 May;181(5):1635-42. doi: 10.1086/315471. Epub 2000 May 15. J Infect Dis. 2000. PMID: 10823763 Clinical Trial.
Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group.
Rezza G, Lepri AC, d'Arminio Monforte A, Pezzotti P, Castelli F, Dianzani F, Lazzarin A, De Luca A, Arlotti M, Leoncini F, Manconi PE, Rizzardini G, Minoli L, Poggio A, Ippolito G, Phillips AN, Moroni M. Rezza G, et al. J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):56-62. doi: 10.1097/00042560-200009010-00008. J Acquir Immune Defic Syndr. 2000. PMID: 11064505
Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?
Pezzotti P, d'Arminio Monforte A, Bugarini R, Rezza G, Arici C, Angarano G, Borderi M, Alberici F, Armignacco O, Menichetti F, Prestileo T, Sighinolfi L, Sinicco A, Resta F, Vigevani M, Ippolito G; ICONA Study Group. Italian Cohort of Naïve Antivirals. Pezzotti P, et al. Eur J Epidemiol. 2000;16(10):919-26. doi: 10.1023/a:1011054418761. Eur J Epidemiol. 2000. PMID: 11338123
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M; ICONA Study Group. Cozzi Lepri A, et al. AIDS. 2001 May 25;15(8):983-90. doi: 10.1097/00002030-200105250-00006. AIDS. 2001. PMID: 11399980 Clinical Trial.
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.
Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A; Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group. Perno CF, et al. J Infect Dis. 2001 Oct 15;184(8):983-91. doi: 10.1086/323604. Epub 2001 Aug 30. J Infect Dis. 2001. PMID: 11574912
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study.
Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, Leoncini F, Scerbo A, Tundo P, Abrescia N, Moroni M; Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study Group. Cozzi-Lepri A, et al. J Infect Dis. 2002 Apr 15;185(8):1062-9. doi: 10.1086/339821. Epub 2002 Apr 1. J Infect Dis. 2002. PMID: 11930316
601 results